CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--May 15, 2017--
Aptar Pharma, a world leader in innovative drug delivery systems, is
pleased to announce the approval by the European Medicines Agency (EMA)
of the first integrated electronic nasal lockout device (e-Lockout)
following a multi-year development with Takeda Pharmaceuticals
International AG. Aptar Pharma agreed to supply Takeda with its
e-Lockout device for a multidose nasal spray version of Instanyl®.
The EMA has granted marketing authorization for this multidose nasal
spray treatment under the name Instanyl DoseGuardTM.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20170515005166/en/
Courtesy of Aptar Pharma
This represents a major milestone for Aptar Pharma, with the e-Lockout
device being the first and only fully integrated electronic nasal drug
delivery device to be approved by a U.S. or European regulatory
authority.
Already available in unidose and multidose nasal spray versions, Takeda
will launch Instanyl® DoseGuard in Europe in several
multidose strengths, all using Aptar Pharma’s patented electronic
lockout system, which marks another product innovation in the management
of breakthrough pain.
Advanced e-Device Technology Ensures Safe Compliance
Instanyl® is a fast-acting nasal opioid approved for
relieving breakthrough pain in adult cancer patients already treated
with opioids for their usual pain. Breakthrough pain is an additional
sudden pain that occurs despite having taken one’s usual pain relieving
medicines.
Aptar Phama’s e-Lockout device uses advanced electronic technology to
help patient compliance in the treatment of chronic disease. Aptar
Pharma’s e-Lockout device is intended to ensure safe patient compliance
by limiting the number of doses available during a 24 hour period.
The system’s built-in lock-out mechanism prevents the device from being
used for a period of time after a pre-defined number of spray
actuations. The electronic display shows the number of priming strokes,
the number of doses left in the device and whether the nasal spray is
locked or ready for use. The e-Lockout also features a child-resistant
cap.
Long-term Strategic Partnership with Takeda
The multi-year supply agreement reinforces a long-standing partnership
between Takeda and Aptar Pharma, who currently supplies Takeda with
unidose and multidose nasal spray devices for Instanyl® in
Europe.
Committed to accompanying pharmaceutical companies throughout their
product lifecycle management, Aptar Pharma continues to partner to
provide customers with innovative and smart solutions to enable safe,
convenient and compliant medication delivery.
“This approval and subsequent product launch underscores Aptar Pharma’s
ability to partner with the pharma industry to bring innovative,
compliant and safer devices through the regulatory authorization
process,” explained Salim Haffar, President, Aptar Pharma. “This is yet
another example of Aptar Pharma’s expertise and technology at the heart
of a new market launch. This is a significant step in strengthening
Aptar Pharma’s credentials in the electronics and connected health
markets. We are pleased to be building on our trusted, long-term
partnership with Takeda,” he added.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a leading global
supplier of a broad range of innovative dispensing and sealing solutions
for the beauty, personal care, home care, prescription drug, consumer
health care, injectables, food and beverage markets. AptarGroup is
headquartered in Crystal Lake, Illinois, with manufacturing facilities
in North America, Europe, Asia and South America. For more information,
visit aptar.com/pharma.
This press release contains forward-looking statements. Words such as
“expects,” “anticipates,” “believes,” “estimates,” “future” and other
similar expressions or future or conditional verbs such as “will,”
“should,” “would” and “could” are intended to identify such
forward-looking statements. Forward-looking statements are made pursuant
to the safe harbor provisions of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934 and are
based on our beliefs as well as assumptions made by and information
currently available to us. Accordingly, our actual results may differ
materially from those expressed or implied in such forward-looking
statements due to known or unknown risks and uncertainties that exist in
our operations and business environment. Additionally, forward-looking
statements include statements that do not relate solely to historical
facts, such as statements which identify uncertainties or trends,
discuss the possible future effects of current known trends or
uncertainties or which indicate that the future effects of known trends
or uncertainties cannot be predicted, guaranteed or assured. For
additional information on these and other risks and uncertainties,
please see our filings with the Securities and Exchange Commission,
including the discussion under “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation
to update any forward-looking statements, whether as a result of new
information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170515005166/en/
Source: AptarGroup, Inc.
Media Contact:
Carolyn Penot
Aptar
Pharma
+33 1 39 17 20 38
carolyn.penot@aptar.com
or
Investor
Relations Contact:
Matthew DellaMaria
AptarGroup,
Inc.
+1 815 477 0424
matt.dellamaria@aptar.com